# | Title | Journal | Year | Citations |
---|
1 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma | New England Journal of Medicine | 2009 | 7,606 |
2 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science | 2007 | 4,187 |
3 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 2,545 |
4 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
5 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,571 |
6 | Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab | Nature Medicine | 2018 | 936 |
7 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 877 |
8 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial | Lancet Respiratory Medicine,the | 2019 | 704 |
9 | Non-small-cell lung cancer | Nature Reviews Disease Primers | 2015 | 653 |
10 | Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis | Journal of Thoracic Oncology | 2017 | 653 |
11 | Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 579 |
12 | Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab | Journal of Clinical Oncology | 2009 | 576 |
13 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2015 | 574 |
14 | A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma | Journal of the National Cancer Institute | 2005 | 567 |
15 | Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system | Cancer | 2002 | 551 |
16 | Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing | Clinical Chemistry | 2013 | 447 |
17 | Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma | JAMA Oncology | 2018 | 437 |
18 | Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial | Lancet, The | 1999 | 436 |
19 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | Annals of Oncology | 2017 | 425 |
20 | Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography | Gut | 2012 | 423 |
21 | Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma | Journal of the National Cancer Institute | 2002 | 384 |
22 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial | Lancet Oncology, The | 2015 | 353 |
23 | Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma | Journal of Clinical Oncology | 2006 | 346 |
24 | Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus | | 1999 | 341 |
25 | Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer | Nature Medicine | 2020 | 322 |
26 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | Journal of Hepatology | 2020 | 310 |
27 | Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors | International Journal of Radiation Oncology Biology Physics | 1995 | 297 |
28 | Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation | International Journal of Radiation Oncology Biology Physics | 2003 | 279 |
29 | Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours | European Journal of Nuclear Medicine and Molecular Imaging | 1996 | 278 |
30 | High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma | Journal of Clinical Oncology | 2008 | 278 |
31 | FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer | Molecular Cancer | 2017 | 276 |
32 | Assessment of Genetic Changes in Hepatocellular Carcinoma by Comparative Genomic Hybridization Analysis | American Journal of Pathology | 1999 | 274 |
33 | Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments | Expert Reviews in Molecular Medicine | 2007 | 266 |
34 | Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study | PLoS ONE | 2013 | 266 |
35 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial | Journal of Thoracic Oncology | 2019 | 260 |
36 | Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy | Journal of Clinical Oncology | 2004 | 255 |
37 | Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | Annals of Hepatology | 2013 | 252 |
38 | Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation | Oncogene | 2006 | 247 |
39 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer | Annals of Oncology | 2014 | 246 |
40 | Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Annals of Oncology | 2018 | 243 |
41 | Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy | American Journal of Gastroenterology | 2015 | 240 |
42 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2022 | 237 |
43 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. | Journal of Clinical Oncology | 2022 | 235 |
44 | Scientific Advances in Lung Cancer 2015 | Journal of Thoracic Oncology | 2016 | 231 |
45 | Overview of current systemic management of EGFR-mutant NSCLC | Annals of Oncology | 2018 | 229 |
46 | Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes | Clinical Chemistry | 2003 | 228 |
47 | Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations | Nature Communications | 2017 | 227 |
48 | Systemic treatment of hepatocellular carcinoma: An EASL position paper | Journal of Hepatology | 2021 | 217 |
49 | Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma | Clinical Cancer Research | 1999 | 216 |
50 | Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer | European Journal of Nuclear Medicine and Molecular Imaging | 1997 | 206 |